Docetaxel Combined With Pulsatile Erlotinib (Tarceva) In Patients With Metastatic Non Small Cell Lung Cancer (NSCLC) (DOPERLO).

Trial Profile

Docetaxel Combined With Pulsatile Erlotinib (Tarceva) In Patients With Metastatic Non Small Cell Lung Cancer (NSCLC) (DOPERLO).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Nov 2012

At a glance

  • Drugs Docetaxel (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms DOPERLO
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 May 2012 Acual end date (31 May 2010) added as reported by European Clinical Trials Database.
    • 15 Jun 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top